Article Figures & Data
Figures
- FIGURE 1.
SFs of MDA-MB-231, 231-H2N, TrR1, and TrR2 human breast cancer cells after treatment with 111In-NLS-trastuzumab alone (radioimmunotherapy [RIT]) (∼0.2 MBq/μg, 100 nmol/L) or 111In-NLS-trastuzumab combined with IC10 concentrations of methotrexate (MTX) (RIT + MTX ), paclitaxel (PAC) (RIT + PAC), or doxorubicin (DOX) (RIT + DOX). IC10 values of each drug for each cell line are shown in Table 1. *P < 0.05, compared with RIT.
- FIGURE 2.
(A) Residual γH2AX-foci in MDA-MB-231, 231-H2N, TrR1, and TrR2 human breast cancer cells 24 h after exposure to 111In-NLS-trastuzumab alone (radioimmunotherapy [RIT]) (100 nmol/L) or 111In-NLS-trastuzumab combined with IC10 concentrations of methotrexate (MTX) (RIT + MTX), paclitaxel (PAC) (RIT + PAC), or doxorubicin (DOX) (RIT + DOX). Number of γH2AX-foci per nucleus is shown as mean ± SEM, and at least 30 nuclei were assessed for γH2AX-foci for each treatment. (B) Induction of γH2AX-foci (green) 24 h after exposure to 111In-NLS-trastuzumab alone or concurrently with MTX, PAC, or DOX. Nuclear DNA was stained with DAPI (blue). *P < 0.05, compared with control, or **P < 0.05, compared with 111In-NLS-trastuzumab.
Tables
- TABLE 1
IC10 and IC50 Values for Methotrexate, Paclitaxel, and Doxorubicin on MDA-MB-231, 231-H2N, TrR1, and TrR2 Human Breast Cancer Cells
Cell line Methotrexate* Paclitaxel Doxorubicin MDA-MB-231 IC10 (μmol/L) 1.01 ± 0.01 0.07 ± 0.03 0.19 ± 0.08 IC50 (μmol/L) 103.3 ± 13.4 0.32 ± 0.13 1.26 ± 0.39 231-H2N IC10 (μmol/L) 12.0 ± 0.23 0.14 ± 0.10 0.02 ± 0.004 IC50 (μmol/L) 120.8 ± 23.3 1.36 ± 0.24 0.16 ± 0.04 TrR1 IC10 (μmol/L) 0.01 ± 0.001 0.12 ± 0.03 0.03 ± 0.01 IC50 (μmol/L) 0.13 ± 0.01 2.01 ± 0.47 0.55 ± 0.25 TrR2 IC10 (μmol/L) 1.13 ± 0.16 0.02 ± 0.01 0.02 ± 0.003 IC50 (μmol/L) 102.4 ± 10.7 0.27 ± 0.06 0.21 ± 0.08 ↵* Values were reported previously in Costantini et al. (16).
Results are expressed as mean ± SEM of 3 measurements performed in duplicate.
- TABLE 2
Radiation Enhancement Ratio (RER) for Methotrexate, Paclitaxel, and Doxorubicin on Human Breast Cancer Cells When Combined with 111In-NLS-Trastuzumab
Cell line Methotrexate Paclitaxel Doxorubicin MDA-MB-231 1.0 1.0 1.1 231-H2N 2.2 1.6 2.7 TrR1 2.0 1.8 2.8 TrR2 1.0 1.0 1.0 RERs were determined by dividing SF of cells treated with 111In-NLS-trastuzumab alone (∼0.2 MBq/μg, 100 nmol/L) by that of cells treated concurrently with 111In-NLS-trastuzumab and IC10 dose for methotrexate, paclitaxel, or doxorubicin. IC10 values for each drug on each cell line are shown in Table 1.
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- Multi-omics analysis of endothelial cells reveals the metabolic diversity that underlies endothelial cell functions
- Cancer Tissue Classification, Associated Therapeutic Implications and PDT as an Alternative
- Experimental Radionuclide Therapy of HER2-Expressing Xenografts Using Two-Step Targeting Nuclisome Particles
- Changes in Lognormal Shape Parameter Guide Design of Patient-Specific Radiochemotherapy Cocktails